The use of equine chondrogenic-induced mesenchymal stem cells as a treatment for osteoarthritis: A randomised, double-blinded, placebo-controlled proof-of-concept study.
Authors: Broeckx S Y, Martens A M, Bertone A L, Van Brantegem L, Duchateau L, Van Hecke L, Dumoulin M, Oosterlinck M, Chiers K, Hussein H, Pille F, Spaas J H
Journal: Equine veterinary journal
Summary
# Editorial Summary Osteoarthritis remains a significant clinical challenge in equine practice, and current therapeutic options have limited efficacy in halting cartilage degradation. Broeckx and colleagues conducted a randomised, double-blinded, placebo-controlled trial in 12 horses with surgically induced metacarpophalangeal joint osteoarthritis, comparing intra-articular injection of allogeneic chondrogenic-induced mesenchymal stem cells combined with equine plasma against saline controls five weeks post-injury. Treatment horses demonstrated clinically meaningful improvements in both subjective and objective lameness measures, alongside significantly increased synovial fluid viscosity, reduced glycosaminoglycan concentrations, and histologically superior articular cartilage preservation characterised by higher cartilage oligomeric matrix protein, collagen type II, and glycosaminoglycan content, with notably less wear-line formation and synovial hyperaemia compared to controls. Whilst no adverse events occurred and these findings are encouraging for future development, the short-term nature of the study and small cohort size warrant cautious interpretation; practitioners should await longer-term, larger-scale efficacy trials before considering this approach standard therapeutic practice. The differentiation between systemically-acting biomarkers and local joint responses observed here suggests cell therapy may exert primary effects through matrix preservation rather than broad anti-inflammatory mechanisms, representing a potentially distinct therapeutic pathway worthy of further investigation.
Read the full abstract on PubMed
Practical Takeaways
- •Allogeneic chondrogenic mesenchymal stem cells combined with plasma may offer a viable intra-articular treatment option for equine osteoarthritis, with improvements in lameness and cartilage quality seen within 11 weeks
- •Treatment was well-tolerated with no serious adverse events, making it a safe option to consider for horses with early to moderate metacarpophalangeal joint disease
- •This proof-of-concept result is promising but based on a small sample size in an artificially-induced model; larger clinical trials are needed before widespread adoption in practice
Key Findings
- •Chondrogenic-induced mesenchymal stem cells combined with equine allogeneic plasma significantly improved visual and objective lameness compared to saline control
- •Intervention group showed significantly higher synovial fluid viscosity and lower glycosaminoglycan concentration
- •Intervention group had significantly less cartilage wear lines and synovial hyperaemia at necropsy
- •Articular cartilage in treated joints contained significantly higher levels of cartilage oligomeric matrix protein, collagen type II, and glycosaminoglycans